行情

ZFGN

ZFGN

Zafgen
NASDAQ

实时行情|Nasdaq Last Sale

1.170
+0.050
+4.46%
交易中 14:25 01/29 EST
开盘
1.120
昨收
1.120
最高
1.180
最低
1.110
成交量
4.56万
成交额
--
52周最高
5.45
52周最低
0.6200
市值
4,372.77万
市盈率(TTM)
-0.8270
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZFGN 新闻

  • 欧洲议会表决通过“脱欧”协议 为英国脱欧铺平道路
  • 新浪财经.1小时前
  • 美国12月份二手房签约量录得2010年以来最大降幅
  • 新浪财经.2小时前
  • 午盘:联储决议在即 美股维持涨势
  • 新浪美股.2小时前
  • 冠状病毒阴云笼罩 苹果公司“复苏”之路前景存疑
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
-0.06%
制药与医学研究
+0.38%

热门股票

名称
价格
涨跌幅

ZFGN 简况

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.
展开

Webull提供Zafgen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。